ClinicalTrials.gg
CompletedNCT01575587Updated Jan 10, 2014

A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men

A Phase 1 interventional study of Abiraterone: Treatment A and Abiraterone: Treatment B in Pharmacology, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Open to male participants aged 25 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-10.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
25 Years to 35 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the effect of timing of food intake on systemic abiraterone exposure observed in healthy adult Japanese and Caucasian men.

Read the detailed description

This is a randomized (individuals will be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), single dose, 4-way crossover study of abiraterone acetate in approximately 48 healthy adult Japanese and Caucasian men. For the crossover design, the treatment sequences are defined as follows: 1 - ADBC, 2 - BACD, 3 - CBDA, and 4 - DCAB; where Treatment A = abiraterone acetate administered in the fasted state, Treatment B = standardized meal administered 1 hour after abiraterone acetate dose, Treatment C = standardized meal administered 2 hours after abiraterone acetate dose, and Treatment D = standardized meal administered 2 hours before and 2 hours after abiraterone acetate dose. This study will consist of a screening period followed by four open-label treatment periods separated by a washout period of at least 14 days between dosing. Eligible participants will be randomly assigned on Day 1 to 1 of 4 treatment sequences that differ with regard to timing of food intake before and/or after dosing with a single dose of 1000 mg of abiraterone acetate. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected during the open-label treatment phase as detailed in the protocol. Safety will be monitored throughout the study. End-of-study assessments will be performed on Day 4 of Period 4 or upon early withdrawal.

02

Conditions studied

  • Pharmacology

Keywords

  • Pharmacology
  • Pharmacokinetics
  • Pharmacodynamics
  • Abiraterone acetate
  • Food intake
  • Caucasion
  • Japanese
  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Caucasian and Japanese male individuals.
  • between 18 and 30 kg/m2.
  • Body weight >=50 kg.
  • A normal 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History of or current medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results.
  • Presence of sexual dysfunction (abnormal libido, erectile dysfunction, etc.) or any medical condition that would affect sexual function.
  • History of alcohol consumption of more than 4 drinks daily within 1 year prior to screening and unwillingness to abstain from alcohol-containing food or beverages from within 24 hours before Day-1 through study completion.
  • History of, or a reason to believe a participant has a history of drug or alcohol abuse within the past 5 years.
  • Positive test for 1 and 2 antibodies, surface antigen, or antibodies.
  • History of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or participant's verbal report.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: Abiraterone: Treatment A

  • Experimental
    Treatment B

    Drug: Abiraterone: Treatment B

  • Experimental
    Treatment C

    Drug: Abiraterone: Treatment C

  • Experimental
    Treatment D

    Drug: Abiraterone: Treatment D

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in mean plasma concentrations of abiraterone

    Time frame: Up to Day 4, treatment period 4

Secondary outcomes

  1. Mean plasma concentrations of abiraterone

    Time frame: Up to Day 4, treatment period 4

  2. Maximum plasma concentration of abiraterone

    Time frame: Up to Day 4, treatment period 4

  3. Time to reach the maximum plasma concentration of abiraterone

    Time frame: Up to Day 4, treatment period 4

  4. Area under the plasma concentration-time curve from time 0 to time the last quantifiable concentration of abiraterone

    Time frame: Up to Day 4, treatment period 4

  5. Area under the plasma concentration-time curve from time 0 to infinite time of abiraterone

    Time frame: Up to Day 4, treatment period 4

  6. Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone

    Time frame: Up to Day 4, treatment period 4

  7. First-order rate constant associated with the terminal portion of the curve of abiraterone

    Time frame: Up to Day 4, treatment period 4

  8. Time to last quantifiable plasma concentration of abiraterone

    Time frame: Up to Day 4, treatment period 4

  9. Percentage of area under the plasma concentration-time curve from time 0 to infinite time obtained by extrapolation of abiraterone

    Time frame: Up to Day 4, treatment period 4

  10. The number of participants affected by an adverse event

    Time frame: Up to the end of the study (4 days after final dose of study drug) or early withdrawal

07

Study locations

1 site
  • Cypress, California, United States
08

References and documents

Publications

  • Inoue K, Shishido A, Vaccaro N, Jiao J, Stieltjes H, Bernard A, Yu M, Chien C. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing. Cancer Chemother Pharmacol. 2015 Jan;75(1):49-58. doi: 10.1007/s00280-014-2616-4. Epub 2014 Oct 25. PubMed 25344090 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2012
First posted
Apr 11, 2012
Start
Jan 2012
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
Jan 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01575587
Responsible party
Sponsor
First posted
Apr 11, 2012
Start date
Jan 2012
Primary completion
May 2012
Completion
May 2012
Last update
Jan 10, 2014

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone

Start the discussion